Discovery and SAR of 1,3,4-thiadiazole derivatives as potent Abl tyrosine kinase inhibitors and cytodifferentiating agents

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 3, 2008, Pages 1207-1211

  Radi, Marco ^a   Crespan, Emmanuele ^b   Botta, Giorgia ^a   Falchi, Federico ^a   Maga, Giovanni ^b   Manetti, Fabrizio ^a   Corradi, Valentina ^a   Mancini, Manuela ^c   Santucci, Maria Alessandra ^c   Schenone, Silvia ^d   Botta, Maurizio ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b CNR   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

Author keywords

1,3,4 Thiadiazoles; Bcr Abl; Leukemia; SAR; Tyrosine kinase inhibitors

Indexed keywords

1,3,4 THIADIAZOLE DERIVATIVE; ABL TYROSINE KINASE INHIBITOR; ANTINEOPLASTIC AGENT; CYTODIFFERENTIATING AGENT; IMATINIB; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CELL; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MOUSE; NONHUMAN; SIMULATION; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; HUMANS; MOLECULAR STRUCTURE; PROTO-ONCOGENE PROTEINS C-ABL; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP; THIADIAZOLES;

MURINAE;

EID: 38749093340     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.11.112     Document Type: Article

References (24)

1. Sawyers C. Nature 432 (2004) 294
2. Schindler T., Bornmann W., Pellicena P., Miller W.T., Clarkson B., and Kuriyan J. Science 289 (2000) 1938
3. Druker B.J. Adv. Cancer Res. 91 (2004) 1
4. Druker B.J., et al. N. Engl. J. Med. 356 (2006) 2408
5. Hochhaus A., Kreil S., Corbin A.S., La Rosee P., Muller M.C., Lahaye T., Hanfstein B., Schoch C., Cross N.C., Berger U., Gschaidmeier H., Druker B.J., and Hehlmann R. Leukemia 16 (2002) 2190
6. Gorre M.E., Mohammed M., Ellwood K., Hsu N., Paquette R., Rao P.N., and Sawyers C.L. Science 293 (2001) 876
7. Azam M., Latek R.R., and Daley J.Q. Cell 112 (2003) 831
8. Tokarski J.S., Newitt J.A., Chang C.Y., Cheng J.D., Wittekind M., Kiefer S.E., Kish K., Lee F.Y.F., Borzillerri R., Lombardo L.J., Xie D., Zhang Y., and Klei H.E. Cancer Res. 66 (2006) 5790
9. Tauchi T., and Ohyashiki K. Int. J. Hematol. 83 (2006) 294
10. Buschbeck M. Drugs R&D 7 (2006) 73
11. Cortes J. Curr. Opin. Hematol. 13 (2006) 79
12. Manetti F., Locatelli G.A., Maga G., Schenone S., Modugno M., Forli S., Corelli F., and Botta M. J. Med. Chem. 49 (2006) 3278
13. Botta, M.; Radi, M.; Manetti, F.; Botta, G.; Maga, G.; Borlak, J. RM2007A000222 (Italian Patent).
14. Gayo L.M., and Suto M.J. Tetrahedron Lett. 38 (1997) 513
15. Determined via HPLC/MS, see Supporting information.
16. Cruciani G., Pastor M., and Guba W. Eur. J. Pharm. Sci. 11 (2000) S29
17. Cruciani G., Crivori P., Carrupt P.-A., and Testa B. J. Mol. Struct. 503 (2000) 17
18. Tokarski J.S., Newitt J., Chang C.Y.J., Cheng J.D., Wittekind M., Kiefer S.E., Kish K., Lee F.Y.F., Borzilerri R., Lombardo L.J., Xie D., Zhang Y., and Klei H.E. Cancer Res. 66 (2006) 5790
19. Details on the computational protocol are reported in the Supporting information.
20. Steady-state kinetic studies conducted on 6a showed that this compound is a competitive inhibitor with respect to ATP (for details, see Supporting information).
21. Nagar B., Bornmann W., Pellicena P., Schindler T., Veach D.R., Miller W.T., Clarkson B., and Kuriyan J. Cancer Res. 62 (2002) 4236
22. Data not shown.
23. Mancini M., Brusa G., Zuffa E., Corrado P., Martinelli G., Grafone T., Barbieri E., and Cantucci M.A. Leuk. Res. 31 (2007) 979
24. Mai A., Massa S., Rotili D., Pezzi R., Bottoni P., Scatena R., Meranerd J., and Broschd G. Bioorg. Med. Chem. Lett. 15 (2005) 4656